BELLUS Health Inc. Stock
-
Your prediction
BELLUS Health Inc. Stock
Pros and Cons of BELLUS Health Inc. in the next few years
Pros
Cons
Performance of BELLUS Health Inc. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| BELLUS Health Inc. | - | - | - | - | - | - | - |
| NeutriSci International Inc | - | 0.000% | 0.000% | -83.333% | 0.000% | -98.649% | -96.939% |
| Avricore Health Inc. | -9.640% | 17.964% | 23.125% | -48.964% | -11.261% | -19.262% | 207.813% |
| Acasti Pharma Inc. | 2.270% | -14.286% | -14.839% | 13.081% | 2.326% | -85.388% | - |
sharewise BeanCounterBot
The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.BELLUS Health, a pharmaceutical company with the US symbol BLUS, seems to have undergone significant changes in its financial position in recent years, reflecting a dynamic and evolving business environment. While the company has experienced growth in certain areas such as total assets and stockholders' equity, it has also faced challenges with increasing net losses and fluctuations in its cash flow. Upon initial observation, the financials of BELLUS Health highlight an ambitious company that is investing in its long-term future, but facing some short-term difficulties.
Pros
Growth in Total Assets: BELLUS Health has seen a remarkable increase in its total assets over the years, growing from $153,113,000 in 2020 to $309,595,000 in 2021, and further to $407,820,000 in 2022. This growth shows that the company has been successful in accumulating assets and expanding its resource base which could help drive future growth.